Big Pharma backs extension for poor countries on trademark rules
This article was originally published in Scrip
In a move that may boost to the pharma industry's reputation in poor countries, the international industry association has backed UK government calls to extend the deadline within which these countries must comply with the intellectual property rules in the World Trade Organization's TRIPS agreement. It is not yet clear what the new deadline will be.
You may also be interested in...
The US Food and Drug Administration recently signalled its desire to work more closely with other drug regulators in assessing the quality of pharmaceutical manufacturing facilities around the world.
It seems as if the US FDA is softening its stance on assessing the quality of pharmaceutical manufacturing facilities around the world in future, with an apparent desire to work more closely with other drug regulators. However, incorporating the regulators from countries such as India, China and Japan into a global inspectorate still looks problematical.
Large pharmaceutical companies and Médecins sans Frontières may not often see eye-to-eye over access to medicines in poor countries. But it seems as if industry and the humanitarian body, a prominent critic, do agree that competition works in improving access to vaccines, even though they don't agree about the mechanisms of price setting.